Nucleo

Name: Nucleo
Brand: Nucleo

AI Native

The online workplace for the life sciences industry connecting people, products and services.

Est 2024|Raised $500K

LinkedIn 4K|Web traffic 6K|FTEs 2|HQ San Francisco, California, US

01Competitive Landscape

Narrative analysis

- Nucleo vs TeraRecon: - TeraRecon is a broad advanced visualization platform used across specialties and includes tools applied in oncology contexts. Nucleo appears to have a narrower focus on oncology CT metrics, which could speed adoption for specific use cases but carries higher integration and enterprise-readiness risk. - Nucleo vs Aidoc: - Aidoc is commonly associated with AI for detection and triage and has commercial distribution experience, including marketplace channels. Nucleo emphasizes quantitative oncology measurements and RECIST-adjacent capabilities rather than acute-finding triage. - Market reality: - Many hospitals have existing PACS and enterprise imaging stacks; adding a specialized oncology quantification layer requires robust integration and clinician validation to achieve routine use.

	Nucleo (vendor product site)	TeraRecon Intuition	Aidoc (clinical AI)
Starting Price	Not publicly listed	Not publicly listed	Published per-scan or per-algorithm pricing available from vendors and marketplaces; enterprise bundles vary
Primary Focus	Oncology CT quantification workflows (body composition, lesion sizing, RECIST-like classification) — vendor-stated	Broad advanced visualization and volumetrics across modalities; enterprise AV workflows	Algorithmic detection/triage workflows across radiology use cases; marketplace procurement available
Key Strength	Vendor-stated focus on oncology CT workflows and reported validation engagements with academic hospitals	Established enterprise footprint with broad feature set and documented regulatory history for some functions	Commercial distribution and marketplace availability; established clinical AI distribution channels
Key Weakness	Limited public evidence on integrations, regulatory status, and security posture; limited independent reviews	Enterprise AV suites can be complex and costly to deploy; adoption requires training and integration work	May not provide comprehensive longitudinal oncology quantification workflows out of the box; marketplace deployments can create workflow duplicates if not integrated carefully

01Competitive Landscape

Narrative analysis

Nucleo vs TeraRecon:
- TeraRecon is a broad advanced visualization platform used across specialties and includes tools applied in oncology contexts. Nucleo appears to have a narrower focus on oncology CT metrics, which could speed adoption for specific use cases but carries higher integration and enterprise-readiness risk.
Nucleo vs Aidoc:
- Aidoc is commonly associated with AI for detection and triage and has commercial distribution experience, including marketplace channels. Nucleo emphasizes quantitative oncology measurements and RECIST-adjacent capabilities rather than acute-finding triage.
Market reality:
- Many hospitals have existing PACS and enterprise imaging stacks; adding a specialized oncology quantification layer requires robust integration and clinician validation to achieve routine use.

	Nucleo (vendor product site)	TeraRecon Intuition	Aidoc (clinical AI)
Starting Price	Not publicly listed	Not publicly listed	Published per-scan or per-algorithm pricing available from vendors and marketplaces; enterprise bundles vary
Primary Focus	Oncology CT quantification workflows (body composition, lesion sizing, RECIST-like classification) — vendor-stated	Broad advanced visualization and volumetrics across modalities; enterprise AV workflows	Algorithmic detection/triage workflows across radiology use cases; marketplace procurement available
Key Strength	Vendor-stated focus on oncology CT workflows and reported validation engagements with academic hospitals	Established enterprise footprint with broad feature set and documented regulatory history for some functions	Commercial distribution and marketplace availability; established clinical AI distribution channels
Key Weakness	Limited public evidence on integrations, regulatory status, and security posture; limited independent reviews	Enterprise AV suites can be complex and costly to deploy; adoption requires training and integration work	May not provide comprehensive longitudinal oncology quantification workflows out of the box; marketplace deployments can create workflow duplicates if not integrated carefully

Nucleo

01Competitive Landscape

Narrative analysis

02Market Map

01Competitive Landscape

Narrative analysis

02Market Map